Vir(US:VIR)2026-01-12 13:07Financial Position - Vir Biotechnology has approximately $781 million in cash and investments, providing a cash runway into Q4 2027[4]. - The company reported approximately $781 million in cash and investments, providing a cash runway into Q4 2027[15][21]. Chronic Hepatitis Delta (CHD) Therapy - The company aims to commercialize its chronic hepatitis delta (CHD) combination therapy to drive near-term revenue sustainability[4]. - The Phase 2 SOLSTICE trial for the CHD therapy shows that 88% of patients receiving the combination of tobevibart and elebsiran achieved undetectable HDV RNA by Week 96, compared to 46% with monotherapy[10]. - Nearly 90% of participants receiving the combination therapy achieved very low HBsAg values by Week 24, maintaining suppression[11]. - The CHD combination therapy is characterized by two complementary mechanisms of action, potentially making it best-in-class[8]. - The combination therapy of tobevibart and elebsiran achieved HDV RNA target not detected (TND) in 88% of participants by Week 96, with approximately 90% achieving HBsAg reductions to <10 IU/mL by Week 24[12]. - Vir Biotechnology has entered a collaboration with Norgine for the commercialization of its CHD regimen in Europe, Australia, and New Zealand, with an initial reimbursement of €55 million and potential milestones up to €495 million[14]. Oncology Pipeline - The oncology pipeline includes significant unmet needs, with projected drug-treated patients for various cancers reaching up to 431,000 for mNSCLC and 271,000 for mCRC by 2032[5]. - Vir Biotechnology's oncology solid tumor portfolio is expected to create sustainable long-term growth through its robust pipeline of cancer immunotherapies[4]. - The masked T-cell engager (TCE) portfolio is expected to drive near-term revenue sustainability and long-term growth through innovative cancer immunotherapies[15]. - The VIR-5500 PSMA-targeted TCE showed a 100% response rate in early dose cohorts, with 58% achieving PSA50 responses[19]. - The company aims to unlock multiple high-value indications with its TCE pipeline, targeting various solid tumors[18]. Research and Development - The company is leveraging AI and machine learning in its research and development efforts to engineer next-generation proteins[2]. - The PRO-XTEN® masking platform enhances the therapeutic index of TCEs, allowing for higher dosing and reduced toxicity[16]. Clinical Milestones - The ECLIPSE clinical program is progressing ahead of schedule, with initial topline data anticipated in Q4 2026 for ECLIPSE 1, and Q1 2027 for ECLIPSE 2 and 3[13]. - Upcoming clinical milestones include topline data for ECLIPSE 1 in Q4 2026 and updates on VIR-5500 and VIR-5818 in early 2026 and 2H 2026, respectively[24][25]. Strategic Collaborations - The company is focusing on strategic collaborations to unlock the value of its pipeline and maximize patient benefits[4]. - Vir Biotechnology retains all commercialization rights in the U.S. and other markets outside of Greater China, while Brii Biosciences holds rights in the Greater China Territory[14].